Xoma has presented the successful six-month results from a Phase IIa clinical trial of Xoma 052 in patients with type 2 diabetes.
The trial included 74 patients and showed the drug was safe and well tolerated with no significant differences in adverse events compared to a placebo.
Go deeper with GlobalData
The results also demonstrated that the drug reduced intraocular inflammation and improved visual acuity.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
